GLP-1 Daily: Ozempic & Wegovy News

GLP-1 Daily: Ozempic & Wegovy News — Lantern Podcasts
  • 0.0 (0)
  • Medicine
  • Updated Daily

GLP-1 Daily: Ozempic & Wegovy News is a weekday briefing on GLP-1 drugs for patients and anyone about to start one. In about eight minutes, anchor Cassidy and cohost Silvara cover what changed today across semaglutide and tirzepatide: Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus and the new oral GLP-1 pills. Expect FDA decisions, clinical trial readouts, supply and shortage updates, safety and side-effect news, and the cost and access story: prior authorization, insurance and Medicaid coverage, employer plans and compounding-pharmacy enforcement. Every efficacy figure is cited, company-reported data is flagged as such, and each story comes back to one question: does this change what you should ask your clinician? No celebrity weight-loss content, before-and-after photos or miracle claims. Not affiliated with Novo Nordisk or Eli Lilly.

  1. 1h ago

    Death Reports Name Bootleg Retatrutide; Walmart's Free GLP-1s Skip Weight Loss

    CBS News obtained two unverified FDA adverse-event reports of deaths after use of products sold as retatrutide, and Walmart will make Ozempic and Mounjaro free in 2027 for employees with type 2 diabetes but still won't cover GLP-1s for weight loss. Plus, a new Annals of Internal Medicine paper finds the Wegovy pill passed 100,000 monthly new prescriptions within two months of launch. In this episode: 1. Two deaths were reported to the FDA. Is the bootleg weight-loss drug "Reta" to blame? - CBS News — Daniel Gilbert Investigative Reporter https://www.cbsnews.com/news/deaths-reported-fda-bootleg-reta-weight-loss-drug/ 2. Walmart employee benefits add no-cost GLP-1s in 2027 — CNBC https://www.cnbc.com/2026/10/13/walmart-glp-1s-inhalers-insulin-employee-benefits.html 3. Oral Semaglutide Obesity Rx Tops 100K Monthly in 2 Months — Medscape https://www.medscape.com/viewarticle/oral-semaglutide-obesity-rx-tops-100k-monthly-2-months-2026a100124c?src=rss Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com

  2. 1d ago

    Retatrutide Black Market Hits Before Approval; Wegovy Pill Generics Far Off

    Eli Lilly is moving against med spas and online sellers marketing its unapproved obesity drug retatrutide, which is still in phase 3. Separately, patent and bioequivalence hurdles suggest a generic Wegovy pill could be more than a decade away. In this episode: Top stories: 1. Lilly is fighting a black market for its new obesity drug even before it launches | PharmaVoice — PharmaVoice https://www.pharmavoice.com/news/lilly-retatrutide-black-market-obesity-drug/832711/?.tsrc=rss 2. Wegovy Pill: Sales, Patents, Generic Hurdles – INTO BIOTECH — INTO BIOTECH https://intobiotech.com/wegovy-pill-generic-barriers/ 3. GLP-1 Benefits Beyond Weight Loss: 2026 Evidence Scorecard — Inside Peptides https://insidepeptides.org/blog/glp-1-drugs-beyond-weight-loss-whats-proven-promising-or-failed/ Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com

  3. 2d ago

    Wegovy Liver-Fat Data at EASD 2026, and What the Wegovy Pill Changes

    Novo Nordisk's post hoc STEP UP analysis at EASD 2026 says Wegovy brought liver fat below 5 percent in 23 of 26 adults with obesity. We weigh that small, company-presented result and what the oral Wegovy pill does and doesn't change for patients. In this episode: Top stories: 1. Wegovy reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat at EASD2026 - Novo - Medical Update Online — Medical Update Online https://medicalupdateonline.com/2026/10/wegovy-reduced-liver-fat-to-normal-levels-in-9-out-of-10-adults-with-obesity-and-excess-liver-fat-at-easd2026-novo/ 2. Step Back: Now that the FDA has approved an oral version of Wegovy, what actually changes for patients compared with the weekly injection—and what still depends on insurance coverage, prescribing decisions, and longer-term evidence? Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com

  4. 5d ago

    Lilly's Oral GLP-1 Orforglipron Clears Heart-Safety Bar in ACHIEVE-4

    Eli Lilly's once-daily oral GLP-1 orforglipron showed no excess cardiovascular risk against insulin glargine in the 2,749-patient ACHIEVE-4 trial, published in The Lancet. That clears a key regulatory hurdle, while an NEJM perspective warns that obesity drug trials aren't built to detect emerging harms. In this episode: Top stories: 1. Step Back: With the FDA warning Empower Pharmacy over what it calls an “inordinate” number of copies of weight-loss drugs, how does the agency distinguish lawful compounding for individual patients from an impermissible copy—and what should patients ask their prescriber or pharmacy to understand which kind they’re receiving? 2. Major trial confirms CVD safety of oral GLP‑1RA — The Limbic https://thelimbic.com/cardiology/major-trial-confirms-cvd-safety-of-oral-glp%e2%80%911ra/ 3. NEJM Interview: Sarah Schmitz on protections for people enrolled in trials of investigational agents for obesity. — Exa https://exa.ai/library/podcast/dzktp1g06zm/episode/rhfh2kxfhx7 Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com

  5. 6d ago

    GLP-1 Users Lost Sight in the Second Eye Sooner, Ophthalmology Study Finds as Vision-Loss Lawsuits Grow

    An American Academy of Ophthalmology meeting study links GLP-1 use to faster second-eye NAION, as federal eye-injury cases climb to 247; plus Medicare Bridge paperwork gaps for cash-pay patients, pharmacists seeing more cash GLP-1 fills, the WHO's first childhood obesity guidelines, and Korea's first homegrown GLP-1 obesity drug. In this episode: 1. GLP-1 Drugs Linked to Faster Vision Loss in the Second Eye, New Study Finds | Newswise — American Academy of Ophthalmology (AAO https://www.newswise.com/articles/glp-1-drugs-linked-to-faster-vision-loss-in-the-second-eye-new-study-finds 2. Medicare’s Missing On-Ramp For Access To GLP-1s For Weight Management | Health Affairs — T. Joseph Mattingly II https://www.healthaffairs.org/content/forefront/medicare-s-missing-ramp-access-glp-1s-weight-management 3. Patients increasingly bypass insurance to pay cash for GLP-1 prescriptions, pharmacists say — Bill Schiffner https://chaindrugreview.com/patients-increasingly-bypass-insurance-to-pay-cash-for-glp-1-prescriptions-pharmacists-say/ 4. Should kids living with obesity be on GLP-1s? New global guidance says yes — in some cases — CBC News https://www.cbc.ca/lite/story/9.7371490 5. MFDS approves Hanmi's EPPE, Korea's first homegrown GLP-1 obesity drug · Local Chorus — Local Chorus https://localchorus.com/story/20261007-kr-ffvtjtxj Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com

  6. Oct 7

    Medicare's $50 GLP-1 Bridge Leaves Out Some Sick Seniors

    Medicare's $50-a-month GLP-1 Bridge pilot is denying some obese seniors who have certain diagnoses, such as severe sleep apnea. Separately, Amylyx will present Phase 3 avexitide data for post-bariatric hypoglycemia at ObesityWeek in November. In this episode: Top stories: 1. Amylyx to Present Phase 3 LUCIDITY Data at ObesityWeek | AMLX Stock News — Stock Titan https://www.stocktitan.net/news/AMLX/amylyx-pharmaceuticals-to-present-topline-data-from-phase-3-lucidity-hre4m1zcnakv.html 2. The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don’t Qualify | Sleep Review — Sleep Review https://sleepreviewmag.com/sleep-treatments/pharmaceuticals/prescription-drugs/medicare-glp-1-discount-not-sleep-apnea/ Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com

  7. Oct 6

    Federal Plans Tie 2027 GLP-1 Coverage to Behavioral Therapy as Diabetes Guidelines Move GLP-1s Up Front

    Federal employee health plans will require documented intensive behavioral therapy before and during anti-obesity drug treatment in 2027, while the new ADA-EASD consensus backs GLP-1 or SGLT2 drugs early in type 2 diabetes. Plus a phase 3 oral GLP-1 pill, a new SELECT heart analysis, and what's known about GLP-1s in children. In this episode: 1. 2027 FEHB Changes: Weight Loss Drug Rules, A New FSA Card, And Plans Leaving | FedSmith.com — Ian Smith https://www.fedsmith.com/2026/10/05/2027-fehb-plan-changes/ 2. The 2026 Diabetes Consensus Backs GLP-1 or SGLT2 Drugs Early, Possibly From Diagnosis, Without Waiting on Metformin | Peptide News Digest — Peptide News Digest https://peptidenewsdigest.org/insights/ada-easd-2026-type-2-diabetes-consensus-glp1-sglt2-earlier/ 3. Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial | Nature Medicine — Nature Medicine https://www.nature.com/articles/s41591-026-04713-y 4. Semaglutide heart benefits not fully explained by weight loss - The Pharmacist — Victoria Vaughan https://www.thepharmacist.co.uk/clinical/nutrition-and-gastroenterology/semaglutide-heart-benefits-not-fully-explained-by-weight-loss/ 5. Weight loss GLP-1s are everywhere and kids are taking them too. 7 things parents should know – PolitiFact — Madison Czopek https://politifact.com/article/2026/oct/05/glp1-weight-loss-children-obesity-risks-parents/ Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com

  8. Oct 5

    Rhode Island Joins the Medicaid GLP-1 Cutbacks as Massachusetts Weight-Loss Use Falls 52%

    Rhode Island Medicaid stopped covering GLP-1s prescribed only for weight loss on October 1, and new Massachusetts data shows weight-loss use fell 52% after insurers pulled back. Plus Cigna employees pressing their own employer, a physician's case against the compounding market, and semaglutide's benefits across frailty levels. In this episode: 1. Rhode Island Medicaid Ends Coverage of Wegovy,… — Inkl https://www.inkl.com/news/rhode-island-medicaid-ends-coverage-of-wegovy-zepbound-and-other-glp-1-drugs-prescribed-only-for-weight-loss 2. GLP-1 use for weight loss plunges 52% in Massachusetts after insurers cut coverage — Morgan Taylor https://www.thecooldown.com/green-business/massachusetts-glp-1-weight-loss-insurers-coverage-cut/ 3. OAC Calls on Cigna to Listen to Employees and Restore GLP-1 Coverage — PR Newswire https://www.prnewswire.com/news-releases/oac-calls-on-cigna-to-listen-to-employees-and-restore-glp-1-coverage-302896674.html 4. I'm an obesity expert and can't wait for the compounding craze to stop | Fortune — Adonis Saremi https://fortune.com/2026/10/03/fda-compounded-glp1-telehealth-enforcement/ 5. Semaglutide Demonstrates Benefits Across Frailty Levels | Obesity | JAMA | JAMA Network — Samantha Anderer https://jamanetwork.com/journals/jama/fullarticle/2854954 Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com

See All (15)

About

GLP-1 Daily: Ozempic & Wegovy News is a weekday briefing on GLP-1 drugs for patients and anyone about to start one. In about eight minutes, anchor Cassidy and cohost Silvara cover what changed today across semaglutide and tirzepatide: Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus and the new oral GLP-1 pills. Expect FDA decisions, clinical trial readouts, supply and shortage updates, safety and side-effect news, and the cost and access story: prior authorization, insurance and Medicaid coverage, employer plans and compounding-pharmacy enforcement. Every efficacy figure is cited, company-reported data is flagged as such, and each story comes back to one question: does this change what you should ask your clinician? No celebrity weight-loss content, before-and-after photos or miracle claims. Not affiliated with Novo Nordisk or Eli Lilly.

Information